MAPT and Cognitive impairment: In addition, monoclonal antibodies such as ABBV-8E12 targeting tau proteins were proved to reduce Tau protein in Cerebrospinal fluid but did not lead to a reverse of the cognitive impairment [378] (NCT03712787).